Meningococcal conjugate vaccine Pregnancy and Breastfeeding Warnings

Brand names: MenQuadfi, Menactra, Menveo

Medically reviewed by Drugs.com. Last updated on Dec 25, 2023.

Meningococcal conjugate vaccine Pregnancy Warnings

Use is recommended only if clearly needed and the benefit outweighs the risk.

AU TGA pregnancy category: B1
US FDA pregnancy category: C

Animal studies did not show treatment related effects on pregnancy or fetal development, parturition, or post-natal development. There are no controlled data in human pregnancy.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Meningococcal conjugate vaccine Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-It is considered unlikely that vaccinating a breast-feeding mother with this product would be harmful to the infant.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer